Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2013-03-20 Major Shareholding Noti…
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Ceasing to be a substantial holder 2 pages 27.2KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 under the Corporations Act 2001, titled 'Notice of ceasing to be a substantial holder.' It details changes in substantial shareholding, including dates, share quantities, and voting power percentages. This type of filing is a notification of changes in major share ownership levels, which aligns with the definition of 'Major Shareholding Notification' (MRQ). The document is not a financial report, earnings release, or management report, but a regulatory notice about shareholding changes.
2013-03-20 English
Change of Director's Interest Notice 2 pages 255.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in a director's relevant interests in securities, including the number of shares held before and after the change, the nature of the change (on-market trade), and other related information. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It does not contain financial statements, earnings data, or management discussion, nor is it an announcement of a report publication. Therefore, the correct classification is Director's Dealing (DIRS). The document length and content fully support this classification with high confidence.
2013-03-17 English
Change in substantial holding 3 pages 35.0KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interests of substantial holder under Corporations Law Section 671B. It details changes in voting power and relevant interests of Investors Mutual Limited in Mayne Pharma Ltd, including previous and present voting power, changes in relevant interests, and associations. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category Major Shareholding Notification (MRQ). The document is not a financial report, earnings release, or management report, but a regulatory disclosure about shareholding changes.
2013-03-14 English
Half Yearly Report and Accounts 32 pages 585.6KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Mayne Pharma Group Limited Interim Results' and includes an Appendix 4D Half Year Report, Directors’ Report, Financial Report, and Auditor’s Independent Review Report for the half-year ended 31 December 2012. It contains detailed financial statements such as the Consolidated Statement of Comprehensive Income, Statement of Financial Position, Directors’ Report, and Auditor’s Report. The document covers a period shorter than a full fiscal year (half-year) and includes substantive financial data and analysis. This matches the definition of an Interim / Quarterly Report (IR). The document is not a brief announcement or a certification letter but a full interim financial report. H1 2013
2013-02-26 English
2013 Half Year Media Release 6 pages 276.3KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Mayne Pharma Reports Interim Result Guidance Achieved' and dated 27 February 2013. It contains detailed financial results for the half-year ended 31 December 2012, including sales revenue, EBITDA, NPAT, segment performance, cash flow, and outlook. The content includes comprehensive financial data and analysis for a period shorter than a full fiscal year, which matches the definition of an Interim / Quarterly Report (IR). The document is 14,288 characters long, well above the threshold for a brief announcement, and contains substantive financial statements and management commentary. Therefore, it is classified as an Interim / Quarterly Report (IR). H1 2013
2013-02-26 English
Appendix 3B 8 pages 220.8KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3B form, which is a standard ASX (Australian Securities Exchange) form used for announcements related to new issues of securities, applications for quotation of additional securities, and agreements related to these securities. The content details the issuance of employee options, terms of the securities, number of securities, and related information for quotation on the ASX. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about capital changes and securities issuance. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length and detail confirm it is the announcement itself, not just a brief notice or report publication announcement.
2013-02-12 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.